Objective: To report the case of a patient treated with leflunomide that presented with chronic diarrhea associated with high teriflunomide blood concentration.
INTRODUCTION
Leflunomide is a disease-modifying antirheumatic drug (DMARD) approved since 1998 for the treatment of rheumatoid arthritis (RA). Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase, an essential enzyme for de novo synthesis of pyrimidines. As a consequence, the division of activated T lymphocytes, which plays an important role in RA pathology, is inhibited [1] . Leflunomide is generally considered when other DMARDs are not effective or not tolerated [2] . It may also be used as an adjunct therapy to methotrexate [3] . One advantage of leflunomide over biological agents is its low cost.
Leflunomide is well absorbed orally, with an estimated bioavailability around 80%.
Leflunomide is a prodrug that is almost completely metabolized in the gut into the active metabolite teriflunomide (also known as A77-1726). This biotransformation occurs by a non-enzymatic reaction in the submucosal wall of the intestinal tract [4] . More than 99% of teriflunomide is bound to proteins and its half-life is approximately 15 days in RA patients (14-18 days) [4, 5] . Teriflunomide is excreted both in urine and in the feces. Its long half-life is thought to be the result of a low hepatic clearance and of an enterohepatic recirculation ( Fig. 1 ). with an important side effect or in women planning a pregnancy [8] .
Otherwise, teriflunomide may be detected in plasma for 2 years after the last dose [6] . Clinical success with cholestyramine decontamination strategy is also reported in patients featuring leflunomide-induced pneumonitis, hepatitis, or vasculitis [7, [9] [10] [11] . However, literature describing the usefulness of teriflunomide blood concentration monitoring is limited.
We describe the case of an 84-year-old woman presenting with severe chronic diarrhea associated with high teriflunomide blood concentration.
CASE PRESENTATION
The patient was an 84-year-old woman who was referred to the internal medicine service of a university teaching hospital for severe chronic diarrhea accompanied with electrolyte imbalance and weight loss. She had been suffering from severe diarrhea (2-5 profuse liquid stools per day) for the past 5 months and her condition progressively deteriorated. Although diarrhea slowly improved during hospitalization, it was not completely resolved.
The patient was discharged on day 41 with loperamide and oral magnesium oxide. Diarrhea resolved around day 56, 26 days after completion of the cholestyramine washout therapy. Loperamide was then stopped. At that time, electrolytes were all normal except for the persistence of hypomagnesemia (0.52 mmol/L), which was attributed to the long-term use of a proton pump inhibitor [12] . Five months later, the patient had recurrence of RA symptoms and oral methotrexate was reintroduced with a 7.5-mg weekly dosage, which was well tolerated and optimized to a 10-mg weekly dosage.
Compliance with Ethics Guidelines
Informed consent was obtained from the patient's family for including the patient in the case study.
DISCUSSION
One of the most common adverse effects of leflunomide therapy for RA is diarrhea. It is often mild, it usually improves after 6 months, and it is rarely a reason for treatment discontinuation [13, 14] .
There are multiple medical causes for chronic diarrhea and leflunomide toxicity Chronic diarrhea and weight loss have been reported in patients taking leflunomide for long periods of time. Two patients taking leflunomide for more than 12 months and presenting chronic diarrhea were reported [13] . Both patients had endoscopy-visible positive colitis induced by leflunomide; one had ulcerative colitis and the other microscopic colitis, which our patient did not have. Blood teriflunomide concentrations were not monitored in these patients [13] . In this case, the colon biopsy showed nonspecific mild acute and subacute colitis. A high teriflunomide blood level (156 mg/L) may have induced colitis, which manifested as a chronic severe diarrhea. However, whether diarrhea is the etiology or the manifestation of the nonspecific mild colitis is not known. Drug-induced colitis does exist, with mofetil mycophenolate for example [13] . In this case, the resolution of diarrhea after a successful cholestyramine washout associated with a decrease of the teriflunomide blood level (6 mg/L) is also suggestive of a leflunomide-induced toxicity. Application of the Naranjo adverse drug reaction probability scale indicates a probable relationship (score of 8).
There are two known possible washout therapies for leflunomide-induced toxicity:
either 8 g of oral cholestyramine three times daily for 11 days or 50 g of activated charcoal four times daily for 11 days [6] . For both these therapies, duration should be modulated according to clinical and laboratory variables [6] . In our case, cholestyramine should have been continued when the second teriflunomide dosage came back to 6 mg/L, as the post-washout targeted dose is less than 0.02 mg/L [8, 15] . Given the patient's improvement, her intolerance to cholestyramine taste and the important decrease in teriflunomide levels, cholestyramine was discontinued after 14 days of washout therapy. The post-washout target of teriflunomide less than 0.02 mg/L was not reached. Thus, the remaining 6 mg/L of teriflunomide might have contributed to the remnant diarrhea. In most of the reported cases of cholestyramine washout therapies were used for 11 days, but teriflunomide levels are not reported or were not determined [7, [9] [10] [11] . One published report showed decreases in levels consistent with ours (100 to 0.057 mg/L after 11 days of cholestyramine washout) [16] .
There is limited data available on the target of teriflunomide blood concentrations for In contrast, the case of an RA patient who mistakenly took 120 mg of leflunomide daily for a month did not report any adverse events despite a teriflunomide dose of 100 mg/L [16] .
Although the patient remained asymptomatic, her blood levels were successfully reduced to 0.057 mg/L with 11 days of cholestyramine [16] . Compliance with ethics guidelines. Informed consent was obtained from the patient's family for including the patient in the case study. 
